Close Menu

NEW YORK (GenomeWeb) – Guardant Health said today that its Guardant360 liquid biopsy test will be covered by health plans associated with technology assessment firm EviCore beginning this summer.

As a result, the test will have become a covered benefit for approximately 150 million people in total.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.